MCL1 and breast carcinoma: For example, in LAML, it is appreciated that BCL-2 expression levels predict sensitivity to BCL-2 inhibition, and recent studies in breast cancer imply that BCL-XL function is critical for sensitivity to MCL-1 inhibition4–6.